1. Scrip
  2. >>Business

Biogen Secures First-Round Patent Win For Tecfidera; One More To Go

 
• By Jessica Merrill

PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.

Biogen's victory over hedge fund manager Kyle Bass' inter partes review (IPR) challenge to a patent protecting its oral multiple sclerosis blockbuster Tecfidera lifts one overhang for the company, but it doesn’t clear the intellectual property headwinds entirely.

On March 21, the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected an IPR challenge against a key patent protecting Tecfidera (dimethyl fumarate) until 2028.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.